PTJ
CTIC

Paul Tudor Jones’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Paul Tudor Jones’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-25,000
Closed -$98K – 1356
2018
Q1 		$98K Buy
+25,000
New +$87.9K ﹤0.01% 923
2016
Q2 		– Sell
-18,850
Closed -$100K – 2130
2016
Q1 		$100K Buy
+18,850
New +$151K ﹤0.01% 1617
2015
Q3 		– Sell
-6,860
Closed -$134K – 1931
2015
Q2 		$134K Sell
6,860
-1,830
-21% -$35.3K ﹤0.01% 1388
2015
Q1 		$157K Buy
+8,690
New +$196K 0.01% 1334

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Paul Tudor Jones's CTIC Position: Q2 2018 in Review

Paul Tudor Jones sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2018, closing a stake of 25,000 shares — an estimated $98K sold.

Paul Tudor Jones first reported a position in CTIC in Q1 2015 and held it in 4 quarters. The position peaked at $157K in Q1 2015. 83 funds tracked by Wall St. Rank hold CTIC as of Q2 2018.

  • Paul Tudor Jones reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2018 after selling out during the quarter.
  • Paul Tudor Jones sold 25,000 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2018, an estimated $98K.
  • Paul Tudor Jones first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2015 and held it in 4 quarters.
  • Paul Tudor Jones's CTI BioPharma Corp. (DE) Common Stock position peaked at $157K in Q1 2015.
  • 83 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2018.

Based on Tudor Investment Corp's 13F filing for Q2 2018, filed 14 Aug 2018.